Pfizer leaps 13% on news that its Covid-19 vaccine is over 90% effective in preventing illness
- Pfizer soared 13% in pre-market trading on Monday after announcing its coronavirus vaccine succeeded in final stage clinical trials.
- The US drugmaker's vaccine is in development with German biotech firm BioNTech, whose shares soared 26%.
- The vaccine won't be immediately available as it still needs to be reviewed by the US Food and Drug Administration.
- Visit Business Insider's homepage for more stories.
Pfizer leapt 13% in pre-market trading on Monday after the drugmaker announced that its experimental Covid-19 vaccine succeeded in late-stage trials.
BioNTech's shares soared 26%.
More to follow
Read the original article on Business Insider
Receive a daily news update on your cellphone. Or get the best of our site emailed to you.
Go to the Business Insider front page for more stories.